BeyondSpring Inc Cash Flow Conversion Efficiency
BeyondSpring Inc cash flow conversion efficiency. Based on the latest financial reports, BeyondSpring Inc (BYSI) has a cash flow conversion efficiency ratio of 0.236x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($-23.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BeyondSpring Inc (2014–2025)
Cash flow conversion efficiency of BeyondSpring Inc from 2014 to 2025. This chart illustrates how BeyondSpring Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BYSI stock price for real-time trading data and today's change.
BeyondSpring Inc Cash Flow Conversion Ratio Explained
BeyondSpring Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BeyondSpring Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeyondSpring Inc ranked by their cash flow conversion efficiency. Also see BeyondSpring Inc (BYSI) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
N/A |
|
UCAL Limited
NSE:UCAL
|
N/A |
|
Jin Yang Pharmaceutical Co. Ltd
KQ:007370
|
0.050x |
|
Drax Group PLC
LSE:DRX
|
0.003x |
|
Daedong Gear Co. Ltd
KQ:008830
|
0.067x |
|
Foods & Inns Limited
NSE:FOODSIN
|
0.092x |
|
ABO Group
BR:ABO
|
0.158x |
|
Etiler İnci Bufe Gida Sanayi ve Dis Ticaret AS
IS:ETILR
|
-0.381x |
Annual Cash Flow Conversion Efficiency for BeyondSpring Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of BeyondSpring Inc from 2014 to 2025. Review BeyondSpring Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.99 Million | $-20.02 Million | 0.835x | -27.49% |
| 2024-12-31 | $-14.29 Million | $-16.44 Million | 1.151x | +63.93% |
| 2023-12-31 | $-23.46 Million | $-16.47 Million | 0.702x | -92.50% |
| 2022-12-31 | $-3.01 Million | $-28.15 Million | 9.362x | +514.63% |
| 2021-12-31 | $20.92 Million | $-47.24 Million | -2.258x | -373.93% |
| 2020-12-31 | $91.82 Million | $-43.74 Million | -0.476x | +69.21% |
| 2019-12-31 | $31.13 Million | $-48.16 Million | -1.547x | -136.33% |
| 2018-12-31 | $-9.38 Million | $-39.95 Million | 4.259x | +514.63% |
| 2017-12-31 | $28.04 Million | $-28.80 Million | -1.027x | +7.78% |
| 2016-12-31 | $12.30 Million | $-13.70 Million | -1.114x | -63.72% |
| 2015-12-31 | $9.66 Million | $-6.57 Million | -0.680x | -657.57% |
| 2014-12-31 | $-9.39 Million | $-1.15 Million | 0.122x | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more